Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STAR: Conbercept for PCV
NCT03159884Phase 4Unknown
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Start
- Oct 2015
- Primary completion
- Jun 2018
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of conbercept in polypoidal choroidal vasculopathy (PCV) (2 arms), sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd. Primary endpoint: Change of Best Corrected Visual Acuity at 48 weeks. Status: unknown.
02
Drugs
conbercept
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on NCT03159884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03159884.